Short communication

PROJECT MANAGEMENT AND ITS ADVANTAGES IN PHARMA INDUSTRY- SHORT COMMUNICATION

Aishwarya Koka, Umamaheswara Rao. G*

In global business portfolio pharmaceutical industry owes a significant position, according to new statistics this prescription of drugs will grow from $950 billion to $1.2 trillion in 2016. Further healthcare has become one of the key priorities of world health sector. The real time metrics are represented in below graphs.¹

The total mix of global spending on medicines will shift toward generics over the next five years, rising from 27% to 36% of the total by 2017, even as brands will continue to account for more than two thirds of spending in developed markets.

The use of generics will be at its highest in pharmerging markets where 63% of the spending will go to generic products. Traditional pharmaceuticals typically used to treat chronic diseases in primary care will increasingly be dispensed as generics and as results total spending will only rise 5 % by 2017 in developed countries.

Special medicines used for conditions that require complex treatment and usually command higher prices will be the biggest driver of branded drug spend growth and most apparent in developed markets where spending in expected to increase by 30% over next five years.²
Figure 2. Pharmaceutical expenditure per capita and population during 2005. 3

Funding: The authors received no direct funding for this research.

Competing Interests: The authors declare no competing interests.

Additional information is available at the end of the article.

Figure 3. Top 20 global therapy areas spending in 2016. 3
By holding this real-time data in mind, global pharma players are in the lookout for new alternate techniques to optimize the development life cycle. The course of NCE drug development and its kinetics towards pharmacological effect on humans is unpredictable and therefore it is critical to have a realistic expectation which can then be followed with generic players but here the inherent problems associated with development are predictable.

In both the development life cycles, there will be a standard set of procedures to deal with, which can completely help to bring down the time associated with development process.

Project management, then, is the application of knowledge, skills, and techniques to execute projects effectively and efficiently. Project management is one of the toolset which squeezes the entire product development procedure, from initiation to closing. It plans the entire R&D process where it executes, monitors, and evaluates the results. At the same time, it optimizes the scope into definite timelines which gives complete activities related to specific milestones. Project management effectively manages the time with proper control on resources in real-time and brings the cross-functional team members together to achieve common goal which significantly helps to drive the project in a smoother way to pull off objectives.

Hence, project management is widely being introduced into the Pharma field as it is not only forming an interface in the sector but is also gaining recognition as one of the most important tools required to run the project activities to definite finish. Project management is gaining popularity widely for the diverse fields it gets associated with not limiting itself to formulation, analytical, clinical, bioanalytical but also paving ways in paths associated with supply chain management, finance, client interactions, marketing strategies, business aspects, etc. In short, a project manager is the owner of a project dealing with every major and minor detail associated with it.

In conclusion, the expansion of project management principles and practitioners within pharmaceutical industries will significantly help to bring down the development life cycle of drugs. Project management should be viewed as a tool that helps organizations to execute designated projects effectively and efficiently. By this fascinated advantages it also creates ample collection of jobs to pharma graduates.
References


2. Murray Aitken, [http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=9f819e464e832410VgnVCM10000076192ca2RCRD&vgnextcchannel=736de5fda6370410VgnVCM10000076192ca2RCRD&vgnextfmt=default](http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=9f819e464e832410VgnVCM10000076192ca2RCRD&vgnextcchannel=736de5fda6370410VgnVCM10000076192ca2RCRD&vgnextfmt=default)


© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to:

Share — copy and redistribute the material in any medium or format

Adapt — remix, transform, and build upon the material for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made.

You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

No additional restrictions

You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.